OCUGEN INC. - COMMON

Ocugen Announces OCU400 Receives Orphan Drug Designations for Retinitis Pigmentosa and Leber Congenital Amaurosis

15 Dec 2022 16:15:49 By Nasdaq GlobeNewswire

Ocugen, Inc. to Ring the Nasdaq Stock Market Closing Bell

13 Dec 2022 07:00:02 By Nasdaq GlobeNewswire

Ocugen Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis

07 Dec 2022 07:00:01 By Nasdaq GlobeNewswire

Ocugen to Present at 3rd Annual Dry AMD Therapeutics Summit

28 Nov 2022 06:30:00 By Nasdaq GlobeNewswire

Ocugen Provides Business Update & Third Quarter 2022 Financial Results

08 Nov 2022 06:30:34 By Nasdaq GlobeNewswire

Ocugen to Host Conference Call on Tuesday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2022 Financial Results

27 Oct 2022 06:30:25 By Nasdaq GlobeNewswire

Ocugen to Host R&D Day in New York City on Tuesday, November 1, 2022

19 Oct 2022 06:30:00 By Nasdaq GlobeNewswire

Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2

12 Oct 2022 16:37:42 By Nasdaq GlobeNewswire

Ocugen, Inc. to Present at Upcoming Vaccines, Cell & Gene Therapy Conferences

06 Oct 2022 07:00:28 By Nasdaq GlobeNewswire

Ocugen, Inc. to Present at Chardan’s 6th Annual Genetic Medicines Conference

29 Sep 2022 06:30:00 By Nasdaq GlobeNewswire

Ocugen Announces Agreement With Washington University in St. Louis for Commercialization of Intranasal COVID-19 Vaccine in U.S., Europe, and Japan

28 Sep 2022 05:30:22 By Nasdaq GlobeNewswire

Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

16 Sep 2022 16:07:00 By Nasdaq GlobeNewswire

Ocugen Announces Publication of a Comprehensive Review of BBV152 in Frontiers in Immunology

14 Sep 2022 05:30:26 By Nasdaq GlobeNewswire

Ocugen CSO to Participate in 3rd Annual Gene Therapy for Ophthalmic Disorders Conference

08 Sep 2022 06:30:00 By Nasdaq GlobeNewswire

Ocugen, Inc. to Present at H.C. Wainwright 24th Annual Global Investment Conference

06 Sep 2022 06:30:00 By Nasdaq GlobeNewswire

Ocugen Appoints Robert J. Hopkins, MD, MPH & TM, FACP, FIDSA, as Chief Medical Officer and Promotes Arun Upadhyay, PhD, to Chief Scientific Officer

01 Sep 2022 06:30:16 By Nasdaq GlobeNewswire

Ocugen CEO to Present at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

12 Aug 2022 06:30:22 By Nasdaq GlobeNewswire

Ocugen Provides Business Update & Second Quarter 2022 Financial Results

05 Aug 2022 06:30:26 By Nasdaq GlobeNewswire

Ocugen To Host Conference Call on Friday, August 5 at 8:30 a.m. ET to Discuss Business Updates and Second Quarter 2022 Financial Results

29 Jul 2022 06:30:58 By Nasdaq GlobeNewswire

Ocugen Announces Publication of Positive Results of COVID-19 Vaccine Trial for Children 2-18 in The Lancet Infectious Diseases

21 Jun 2022 06:00:00 By Nasdaq GlobeNewswire